Abivax SA American Depositary Shares (ABVX)vsInsmed Inc (INSM)
ABVX
Abivax SA American Depositary Shares
$110.70
+0.48%
HEALTHCARE · Cap: $8.73B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 11318% more annual revenue ($606.42M vs $5.31M). ABVX leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
ABVX
Avoid22
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
Trading at 14.5x book value
0.0% earnings growth
0.0% margin — thin
Weak financial health signals
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : ABVX
ABVX has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : ABVX
The primary concerns for ABVX are Price/Book, EPS Growth, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
ABVX profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
ABVX generates stronger free cash flow (-71M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 22/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Abivax SA American Depositary Shares
HEALTHCARE · BIOTECHNOLOGY · USA
Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections, with its lead candidate ABX464 currently in clinical trials for ulcerative colitis and other indications. The company’s innovative approach integrates antibody-mediated therapies with proprietary compounds, targeting significant unmet medical needs in the healthcare market. With a robust pipeline and a dedicated scientific team, Abivax stands as an intriguing investment opportunity for institutional investors seeking to engage in the burgeoning immunotherapy sector.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?